Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUGB: Systemic Therapy +/- RT in Unresectable Gallbladder Cancer
NCT06214572Phase 3Recruiting
- Sponsor
- Tata Memorial Centre
- Start
- Mar 2024
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Tata Memorial Centre. Primary endpoints: Overall Survival at 2 years and Progression-Free Survival at 2 years. Started Mar 2024; status: recruiting.
Beyond the preview
Go deeper on NCT06214572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06214572.